Banner Slide

Going further to bring better days to even more people with cancer

Our Business

The Helsinn Group is one of the world's leading supportive cancer care companies, with a comprehensive portfolio of medicines and therapies helping to improve the lives of patients in countries around the world.

Learn more

Corporate Social Responsibility and Sustainability

Sustainability is becoming an increasingly central part of Helsinn’s culture and business strategy. Integrity, quality and respect have always been at the core of our business, but increasingly, organisations are aware that they function as part of an ecosystem to which they have a responsibility. Care for the communities in which we operate, and stewardship of our environment, are as important to our long-term future as the economic bottom line.

Learn more

Our Products

The strength of the Helsinn model is reflected in the product candidates that we have transformed into sustainable market successes.

Learn more

Our Building Blocks

News & Events

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and pal...

Akynzeo® for injection received a permanent J code,  J1454, in the US, by the Centers for Medicare and Medicaid Services...

Read more

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine i...

LUGANO, Switzerland and San Diego, USA, December 3, 2018: Helsinn Group, a Swiss pharmaceutical group focused on buildin...

Read more

Helsinn and Mundipharma China Pharmaceutical announce tha approval of ALOXI®IV b...

Approval by the National Medical Products Administration (NMPA) brings ALOXI® to a large new patient population ALOXI® i...

Read more

Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innov...

The award will be presented to the Patient Entrepreneur demonstrating outstanding science and potential to bring their i...

Read more

ONO Submits an Application for Manufacturing and Marketing Approval of Anamoreli...

Ono Pharmaceutical Co., Ltd. (Osaka, Japan, President and Representative Director: Gyo Sagara; “ONO”) announced today th...

Read more